NCT03395223View on ClinicalTrials.gov

MEthylene Blue In Patients With Acquired Methemoglobinemia

PHASE4CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 6, 2018

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Acquired Methaemoglobinaemia
Interventions
DRUG

Methylene Blue

Administration of Methylene Blue to treat acquired methaemoglobinaemia

Trial Locations (1)

75475

Hôpital Lariboisière, Paris

All Listed Sponsors
lead

Provepharm SAS

INDUSTRY

NCT03395223 - MEthylene Blue In Patients With Acquired Methemoglobinemia | Biotech Hunter | Biotech Hunter